CNSP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.07%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

CNS Pharmaceuticals Insider Trading History Chart

CNS Pharmaceuticals Share Price & Price History

^$1.13

▼ -0.12 (-9.60%)

As of 04/3/2025 05:00 PM ET

Days: 30 | 90 | 365

CNS Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/22/2023	Christopher Downs	CFO	Buy	10	$3,175.00	$31,750.00	14
8/16/2023	John M Climaco	CEO	Buy	1	$4,500.00	$4,500.00	19
4/19/2023	Jerzy Gumulka	Director	Buy	1	$4,250.00	$4,250.00	3
4/17/2023	Christopher Downs	CFO	Buy	1	$8,000.00	$8,000.00	3
4/12/2023	John M Climaco	CEO	Buy	6	$1,725.00	$10,350.00	18
4/10/2023	Jerzy Gumulka	Director	Buy	2	$1,850.00	$3,700.00	2
3/27/2023	Waldemar Priebe	Major Shareholder	Sell	2	$2,725.00	$5,450.00	66
3/24/2023	Waldemar Priebe	Major Shareholder	Sell	2	$2,700.00	$5,400.00	68
3/22/2023	Waldemar Priebe	Major Shareholder	Sell	2	$2,700.00	$5,400.00	74
3/20/2023	Waldemar Priebe	Major Shareholder	Sell	2	$2,700.00	$5,400.00	78
3/17/2023	Waldemar Priebe	Major Shareholder	Sell	2	$2,825.00	$5,650.00	80
3/15/2023	Waldemar Priebe	Major Shareholder	Sell	2	$3,050.00	$6,100.00	84
3/13/2023	Waldemar Priebe	Major Shareholder	Sell	2	$3,250.00	$6,500.00	88
3/10/2023	Waldemar Priebe	Major Shareholder	Sell	2	$3,225.00	$6,450.00	90

See Full Table

SEC Filings (Institutional Ownership Changes) for CNS Pharmaceuticals (NASDAQ:CNSP)

14.02% of CNS Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

CNS Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/18/2025	Connective Capital Management LLC	280,055	$34K	0.0%	N/A	0.487%
2/17/2025	Citadel Advisors LLC	321,874	$39K	0.0%	N/A	0.560%
2/14/2025	Jane Street Group LLC	419,737	$51K	0.0%	+1,712.3%	0.730%
2/14/2025	Integrated Wealth Concepts LLC	250,000	$30K	0.0%	N/A	0.435%
2/13/2025	XTX Topco Ltd	294,919	$36K	0.0%	N/A	0.513%
2/12/2025	Geode Capital Management LLC	387,064	$47K	0.0%	+90.5%	0.673%
2/7/2025	Wealthfront Advisers LLC	216,046	$26K	0.0%	N/A	0.376%
5/20/2024	Virtu Financial LLC	94,246	$34K	0.0%	+616.6%	0.795%
2/13/2024	Armistice Capital LLC	122,000	$0.16M	0.0%	N/A	1.965%
1/17/2024	Smith Anglin Financial LLC	50,000	$64K	0.0%	N/A	0.952%
8/7/2023	Acadian Asset Management LLC	22,292	$49K	0.0%	N/A	1.000%
7/12/2023	FSM Wealth Advisors LLC	16,334	$38K	0.0%	N/A	0.732%
9/17/2021	Virtu Financial LLC	20,745	$41K	0.0%	-49.8%	0.076%
8/13/2021	Renaissance Technologies LLC	432,109	$0.85M	0.0%	-40.2%	1.704%
8/13/2021	Geode Capital Management LLC	100,196	$0.20M	0.0%	+64.8%	0.395%
8/13/2021	Vanguard Group Inc.	599,309	$1.18M	0.0%	+326.6%	2.363%
8/11/2021	Commonwealth Equity Services LLC	20,000	$39K	0.0%	N/A	0.079%
5/19/2021	Virtu Financial LLC	41,310	$99K	0.0%	N/A	0.163%
5/18/2021	Citadel Advisors LLC	92,404	$0.22M	0.0%	N/A	0.364%
5/18/2021	Jane Street Group LLC	13,747	$33K	0.0%	N/A	0.054%
5/17/2021	Goldman Sachs Group Inc.	11,566	$28K	0.0%	N/A	0.046%
5/13/2021	Renaissance Technologies LLC	722,760	$1.73M	0.0%	N/A	2.850%
5/13/2021	Bank of New York Mellon Corp	43,659	$0.10M	0.0%	N/A	0.172%
5/12/2021	Northern Trust Corp	32,094	$77K	0.0%	N/A	0.127%
5/12/2021	Geode Capital Management LLC	60,784	$0.15M	0.0%	N/A	0.240%

Data available starting January 2016

See Full Table

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Today's Range

Now: $1.13

$1.10

$1.24

50 Day Range

MA: $3.55

$1.13

$7.13

52 Week Range

Now: $1.13

$1.10

$800.00

Volume

118,165 shs

Average Volume

278,850 shs

Market Capitalization

$3.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.72

Who are the company insiders with the largest holdings of CNS Pharmaceuticals?: CNS Pharmaceuticals' top insider shareholders include:
John M Climaco (CEO)
Christopher Downs (CFO)
Jerzy Gumulka (Director)
Learn More about top insider investors at CNS Pharmaceuticals.